Eterna Therapeutics Inc
NASDAQ:ERNA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Eterna Therapeutics Inc
Total Current Assets
Eterna Therapeutics Inc
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Eterna Therapeutics Inc
NASDAQ:ERNA
|
Total Current Assets
$3.4m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-10%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Assets
$29.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
6%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Assets
$18.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Assets
$29.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-3%
|
|
|
Exact Sciences Corp
NASDAQ:EXAS
|
Total Current Assets
$1.6B
|
CAGR 3-Years
17%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
17%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Assets
$11.2B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
23%
|
|
Eterna Therapeutics Inc
Glance View
Eterna Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Brooklyn, New York and currently employs 10 full-time employees. Eterna Therapeutics Inc., formerly Brooklyn ImmunoTherapeutics Inc., is a clinical-stage biopharmaceutical company. The firm is focused on developing cytokine-based therapies for treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. Its lead product candidate, IRX-2, is a cytokine therapy, to treat patients with head and neck cancer. IRX-2 is a mixed, human-derived cytokine product with multiple active constituents including Interleukin-2 (IL2) and other key cytokines, which restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. The firm also has multiple cell and gene-editing therapies in preclinical development for various indications, including acute respiratory distress syndrome, solid tumor indications, as well as in vivo gene-editing therapies for rare genetic diseases. Its subsidiaries include Brooklyn ImmunoTherapeutics LLC, Novellus, Inc. and Novellus Therapeutics, Ltd.
See Also
What is Eterna Therapeutics Inc's Total Current Assets?
Total Current Assets
3.4m
USD
Based on the financial report for Sep 30, 2025, Eterna Therapeutics Inc's Total Current Assets amounts to 3.4m USD.
What is Eterna Therapeutics Inc's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
-10%
Over the last year, the Total Current Assets growth was -29%. The average annual Total Current Assets growth rates for Eterna Therapeutics Inc have been -40% over the past three years , 4% over the past five years , and -10% over the past ten years .
